<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00117819</url>
  </required_header>
  <id_info>
    <org_study_id>At-Risk</org_study_id>
    <nct_id>NCT00117819</nct_id>
  </id_info>
  <brief_title>A Study of Brain Imaging With Nuclear Medicine Technology in Individuals With and at Risk for Parkinson's Disease</brief_title>
  <official_title>Dynamic SPECT Imaging With [123I] B-CIT in Individuals With Parkinsonian Syndrome (PS) and in Individuals at Risk for Parkinsonian Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute for Neurodegenerative Disorders</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Albany Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute for Neurodegenerative Disorders</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study involves study participants who have been clinically diagnosed with parkinsonian
      syndrome or who are at-risk for parkinsonian syndrome, have a family history of parkinsonian
      syndrome or exposure to environmental toxins potentially associated with parkinsonian
      syndrome. Participants will have brain imaging to assess dopamine transporter density. The
      imaging data coupled with family history and environmental exposure data may provide
      important information about potential risk factors for parkinsonian syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The brain imaging is conducted at the Institute for Neurodegenerative Disorders in New Haven,
      Connecticut. The imaging procedure occurs over a two day period.

      On the first day participants are injected with [123I]ß CIT, an investigational radioactive
      material that localizes in the brain. Study participants will also have a thorough neurologic
      examination and standard neuropsychological testing, including testing of memory,
      concentration, abstraction and visual spatial functions.

      Twenty-four hours later study participants return to the Institute for Neurodegenerative
      Disorders where an investigational scanning procedure will be used to obtain SPECT (single
      photon emission computed tomography) images of the brain.

      Participants may be contacted to repeat these procedures every 12 to 18 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2001</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CIT uptake is the Specific: Nondisplaceable striatal uptake ratio</measure>
    <time_frame>2 yrs</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CIT uptake measures from at-risk individuals will be compared with healthy subjects.</measure>
    <time_frame>2 yrs</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">232</enrollment>
  <condition>Parkinsonian Syndrome</condition>
  <arm_group>
    <arm_group_label>[123I]ß CIT and SPECT imaging</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To assess [123I]ß-CIT and SPECT imaging</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[123I]ß CIT and SPECT imaging</intervention_name>
    <description>To assess [123I]ß CIT and SPECT imaging</description>
    <arm_group_label>[123I]ß CIT and SPECT imaging</arm_group_label>
    <other_name>[123I]ß CIT</other_name>
    <other_name>SPECT imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  22 years or older

          -  A clinical diagnosis of Parkinson's disease (PD), positive family history of PD and/or
             potential exposure to environmental toxins

          -  Normal screening laboratory studies

        Exclusion Criteria:

          -  Pregnancy

          -  Psychiatric disease other than history of depression

          -  Significant medical disease including abnormalities on screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth L. Marek, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>President and Senior Scientist</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute for Neurodegenerative Disorders</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Koller WC, Langston JW, Hubble JP, Irwin I, Zack M, Golbe L, Forno L, Ellenberg J, Kurland L, Ruttenber AJ, et al. Does a long preclinical period occur in Parkinson's disease? Neurology. 1991 May;41(5 Suppl 2):8-13. Review.</citation>
    <PMID>2041599</PMID>
  </reference>
  <reference>
    <citation>Marek, K., J. Seibyl, et al. (1999). &quot;[123I] ß-CIT/SPECT: Assessment of determinants of variability in progression of Parkinson's disease.&quot; Neurology 52: A91-92.</citation>
  </reference>
  <reference>
    <citation>Marek, K., J. Seibyl, et al. (1996). &quot;Dopamine transporter and receptor imaging in Parkinsonism. (Presented at the 4th International Congress of Movement Disorders, Vienna, Austria; June, 1996.).&quot; Mov Dis 6.</citation>
  </reference>
  <reference>
    <citation>Morrish PK, Sawle GV, Brooks DJ. An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain. 1996 Apr;119 ( Pt 2):585-91.</citation>
    <PMID>8800950</PMID>
  </reference>
  <reference>
    <citation>Seibyl JP, Marek KL, Quinlan D, Sheff K, Zoghbi S, Zea-Ponce Y, Baldwin RM, Fussell B, Smith EO, Charney DS, van Dyck C, et al. Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol. 1995 Oct;38(4):589-98. Erratum in: Ann Neurol. 1996 Mar;39(3):417. van Dyck, C [added].</citation>
    <PMID>7574455</PMID>
  </reference>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2005</study_first_submitted>
  <study_first_submitted_qc>June 30, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2005</study_first_posted>
  <disposition_first_submitted>April 9, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>April 9, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 2, 2014</disposition_first_posted>
  <last_update_submitted>April 9, 2014</last_update_submitted>
  <last_update_submitted_qc>April 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institute for Neurodegenerative Disorders</investigator_affiliation>
    <investigator_full_name>Kenneth Marek, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>parkinson</keyword>
  <keyword>family history</keyword>
  <keyword>diagnosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

